Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Operating Leases (Tables)

Operating Leases (Tables)

3 Months Ended

Mar. 31, 2024

Operating leases

Schedule of weighted-average remaining lease term and the weighted-average discount rate


			Three months ended
			March 31,
			2024			2023
Lease cost:
Operating lease cost			$	1,682		$	1,060
Short-term lease cost				59			137
			$	1,741		$	1,197

			March 31,
			2024			2023

Weighted-average remaining lease term - operating leases			5.3 years			6.7 years
Weighted-average discount rate - operating leases			8.0%			6.8%

Schedule of maturities of operating lease liabilities


			Three months ended
			March 31,
			2024			2023
Lease cost:
Operating lease cost			$	1,682		$	1,060
Short-term lease cost				59			137
			$	1,741		$	1,197

			March 31,
			2024			2023

Weighted-average remaining lease term - operating leases			5.3 years			6.7 years
Weighted-average discount rate - operating leases			8.0%			6.8%

The maturities of operating lease liabilities as of March 31, 2024 are as follows (in thousands):


		Operating leases

2024		$	5,189
2025			5,561
2026			4,362
2027			5,560
2028			2,141
after 2028			5,499
Total lease payments			28,312
Less: Imputed interest			(4,620)
Present value of lease liability		$	23,692